Models:
Philip Bordner
philipB/
NER-medical-text
0
Downloads: 1
Diff of /html_files/25410883.html [000000] .. [c0f169]

Switch to unified view

a b/html_files/25410883.html 

  1
  





  
  

  2
  
    <!DOCTYPE html>





  
  

  3
  
    <html>





  
  

  4
  
    <head>





  
  

  5
  
        <meta charset="utf-8">





  
  

  6
  
        <title>25410883 Visualization</title>





  
  

  7
  
    </head>





  
  

  8
  
    <body>





  
  

  9
  
        <h1>25410883 Visualization</h1>





  
  

  10
  
        <p><a href="main.html">Back to Main Page</a></p>





  
  

  11
  
        <div class="entities" style="line-height: 2.5; direction: ltr">A 





  
  

  12
  
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  13
  
    77





  
  

  14
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span>





  
  

  15
  
</mark>





  
  

  16
  
-





  
  

  17
  
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  18
  
    year





  
  

  19
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span>





  
  

  20
  
</mark>





  
  

  21
  
-





  
  

  22
  
<mark class="entity" style="background: #f6c3d0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  23
  
    old





  
  

  24
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Age</span>





  
  

  25
  
</mark>





  
  

  26
  
 





  
  

  27
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  28
  
    woman





  
  

  29
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sex</span>





  
  

  30
  
</mark>





  
  

  31
  
 with 





  
  

  32
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  33
  
    dysphagia





  
  

  34
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  35
  
</mark>





  
  

  36
  
 





  
  

  37
  
<mark class="entity" style="background: #77c5d5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  38
  
    presented





  
  

  39
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Clinical_event</span>





  
  

  40
  
</mark>





  
  

  41
  
 with a 





  
  

  42
  
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  43
  
    two





  
  

  44
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span>





  
  

  45
  
</mark>





  
  

  46
  
-





  
  

  47
  
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  48
  
    week





  
  

  49
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span>





  
  

  50
  
</mark>





  
  

  51
  
 





  
  

  52
  
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  53
  
    history





  
  

  54
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span>





  
  

  55
  
</mark>





  
  

  56
  
 of 





  
  

  57
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  58
  
    rash





  
  

  59
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  60
  
</mark>





  
  

  61
  
 characterized by 





  
  

  62
  
<mark class="entity" style="background: #a0ced9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  63
  
    brown





  
  

  64
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Color</span>





  
  

  65
  
</mark>





  
  

  66
  
 





  
  

  67
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  68
  
    plaques





  
  

  69
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  70
  
</mark>





  
  

  71
  
 with 





  
  

  72
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  73
  
    erythematous





  
  

  74
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  75
  
</mark>





  
  

  76
  
 





  
  

  77
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  78
  
    borders





  
  

  79
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  80
  
</mark>





  
  

  81
  
 and 





  
  

  82
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  83
  
    overlying





  
  

  84
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  85
  
</mark>





  
  

  86
  
 





  
  

  87
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  88
  
    thick





  
  

  89
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  90
  
</mark>





  
  

  91
  
 





  
  

  92
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  93
  
    scales





  
  

  94
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  95
  
</mark>





  
  

  96
  
 involving the 





  
  

  97
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  98
  
    face





  
  

  99
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  100
  
</mark>





  
  

  101
  
 and a prior 





  
  

  102
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  103
  
    percutaneous





  
  

  104
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  105
  
</mark>





  
  

  106
  
 





  
  

  107
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  108
  
    endoscopic





  
  

  109
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  110
  
</mark>





  
  

  111
  
 





  
  

  112
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  113
  
    gastrostomy





  
  

  114
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  115
  
</mark>





  
  

  116
  
 (





  
  

  117
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  118
  
    PEG





  
  

  119
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  120
  
</mark>





  
  

  121
  
) tube 





  
  

  122
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  123
  
    site





  
  

  124
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  125
  
</mark>





  
  

  126
  
 (Fig.1a, c).</br>No 





  
  

  127
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  128
  
    oral





  
  

  129
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  130
  
</mark>





  
  

  131
  
 or 





  
  

  132
  
<mark class="entity" style="background: #9ddfd3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  133
  
    conjunctival





  
  

  134
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Biological_structure</span>





  
  

  135
  
</mark>





  
  

  136
  
 





  
  

  137
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  138
  
    involvement





  
  

  139
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  140
  
</mark>





  
  

  141
  
 was present.</br>She had been receiving 





  
  

  142
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  143
  
    parenteral





  
  

  144
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  145
  
</mark>





  
  

  146
  
 





  
  

  147
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  148
  
    nutrition





  
  

  149
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  150
  
</mark>





  
  

  151
  
 for 





  
  

  152
  
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  153
  
    two





  
  

  154
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span>





  
  

  155
  
</mark>





  
  

  156
  
 





  
  

  157
  
<mark class="entity" style="background: #ffdfba; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  158
  
    months





  
  

  159
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Duration</span>





  
  

  160
  
</mark>





  
  

  161
  
 following removal of the 





  
  

  162
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  163
  
    PEG





  
  

  164
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  165
  
</mark>





  
  

  166
  
 





  
  

  167
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  168
  
    tube





  
  

  169
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  170
  
</mark>





  
  

  171
  
 due to 





  
  

  172
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  173
  
    infection





  
  

  174
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  175
  
</mark>





  
  

  176
  
.</br>Although the differential diagnosis included 





  
  

  177
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  178
  
    drug





  
  

  179
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  180
  
</mark>





  
  

  181
  
 





  
  

  182
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  183
  
    hypersensitivity





  
  

  184
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  185
  
</mark>





  
  

  186
  
, 





  
  

  187
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  188
  
    autoimmune





  
  

  189
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  190
  
</mark>





  
  

  191
  
 





  
  

  192
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  193
  
    disorders





  
  

  194
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  195
  
</mark>





  
  

  196
  
 and 





  
  

  197
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  198
  
    nutritional





  
  

  199
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  200
  
</mark>





  
  

  201
  
 





  
  

  202
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  203
  
    deficiency





  
  

  204
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  205
  
</mark>





  
  

  206
  
, the 





  
  

  207
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  208
  
    rash





  
  

  209
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  210
  
</mark>





  
  

  211
  
 appearance was most consistent with 





  
  

  212
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  213
  
    acrodermatitis





  
  

  214
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  215
  
</mark>





  
  

  216
  
 





  
  

  217
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  218
  
    enteropathica





  
  

  219
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  220
  
</mark>





  
  

  221
  
-like 





  
  

  222
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  223
  
    eruption





  
  

  224
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  225
  
</mark>





  
  

  226
  
 secondary to 





  
  

  227
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  228
  
    zinc





  
  

  229
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  230
  
</mark>





  
  

  231
  
 





  
  

  232
  
<mark class="entity" style="background: #c4b7ea; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  233
  
    deficiency





  
  

  234
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Disease_disorder</span>





  
  

  235
  
</mark>





  
  

  236
  
.</br>Her 





  
  

  237
  
<mark class="entity" style="background: #ffb347; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  238
  
    serum





  
  

  239
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Detailed_description</span>





  
  

  240
  
</mark>





  
  

  241
  
 





  
  

  242
  
<mark class="entity" style="background: #c5b4e3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  243
  
    zinc





  
  

  244
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Diagnostic_procedure</span>





  
  

  245
  
</mark>





  
  

  246
  
 level was 





  
  

  247
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  248
  
    12





  
  

  249
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  250
  
</mark>





  
  

  251
  
 





  
  

  252
  
<mark class="entity" style="background: #f4b3c2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  253
  
    mcg/dL





  
  

  254
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Lab_value</span>





  
  

  255
  
</mark>





  
  

  256
  
 (normal, 55–150 mcg/dL), and the 





  
  

  257
  
<mark class="entity" style="background: #bde0fe; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  258
  
    rash





  
  

  259
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Sign_symptom</span>





  
  

  260
  
</mark>





  
  

  261
  
 resolved 





  
  

  262
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  263
  
    within





  
  

  264
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  265
  
</mark>





  
  

  266
  
 





  
  

  267
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  268
  
    one





  
  

  269
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  270
  
</mark>





  
  

  271
  
 





  
  

  272
  
<mark class="entity" style="background: #f1f0d2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  273
  
    week





  
  

  274
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Date</span>





  
  

  275
  
</mark>





  
  

  276
  
 of 





  
  

  277
  
<mark class="entity" style="background: #f7a399; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  278
  
    parenteral





  
  

  279
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Administration</span>





  
  

  280
  
</mark>





  
  

  281
  
 





  
  

  282
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  283
  
    zinc





  
  

  284
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  285
  
</mark>





  
  

  286
  
 





  
  

  287
  
<mark class="entity" style="background: #f9d5e5; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">





  
  

  288
  
    supplementation





  
  

  289
  
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">Medication</span>





  
  

  290
  
</mark>





  
  

  291
  
 (Fig.1b, d).</br>Zinc is essential for protein synthesis and wound healing.</br>Acrodermatitis enteropathica presents in infancy as a periorificial desquamative dermatitis, resulting from an autosomal recessive mutation that impairs zinc absorption. A similar syndrome may occur due to nutritional zinc deficiency, and has been reported in the setting of parenteral nutrition that fails to include zinc supplementation; a prompt response to supplementation helps to confirm the diagnosis.</br>A recent national shortage of parenteral zinc in the United States likely contributed to this patient’s presentation.</br></div>





  
  

  292
  
    </body>





  
  

  293
  
    </html>





  
  

  294